Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 94

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 94
---

be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability.
To protect our proprietary position, we file patent applications in the United States and abroad related to our product candidates
that are important to our business; we may in the future also license or purchase patent applications filed by others. If we are unable
to secure or maintain patent protection with respect to our technology and any proprietary products and technology we develop, our business,
financial condition, results of operations and prospects could be materially harmed.

We cannot provide any assurances
that any of our current or future patents have or will include claims with a scope sufficient to protect our current and future product
candidates or otherwise provide any competitive advantage. In addition, the laws of foreign countries may not protect our rights to the
same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural
expiration of a patent is generally 20 years after its earliest U.S. non-provisional filing date. Various extensions may be
available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development,
testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such
candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from
commercializing products similar or identical to ours. Moreover, some of our patents and patent applications are, and may in the future
be, owned by or co-owned with third parties. Any of the foregoing could have a material adverse effect on our competitive position, business,
financial conditions, results of operations and prospects.

The patent prosecution process
is complex, expensive, time-consuming and inconsistent across jurisdictions. We may not be able to file, prosecute, maintain, enforce,
or license all necessary or desirable patent rights at a commercially reasonable cost or in a timely manner. In addition, we may not
pursue or obtain patent protection in all relevant markets. It is possible that we will fail to identify important patentable aspects
of our R&D efforts in time to obtain any patent protection. While we enter into non-disclosure and confidentiality agreements with
parties who have access to confidential or patentable aspects of our R&D efforts, including for example, our employees, former employees,
corporate collaborators, external academic scientific collaborators, CROs, contract manufacturers, consultants, advisors and